Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment
Abstract Oral mucositis (OM) is one of the most common complications associated with chemotherapy. Here, we evaluated whether systemic dexamethasone (DEX) dosage in prophylactic antiemetics affected the incidence of OM in anthracycline-containing regimens. Patients receiving anthracycline-containing...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-16935-4 |
| _version_ | 1828329319309508608 |
|---|---|
| author | Yoshitaka Saito Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara |
| author_facet | Yoshitaka Saito Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara |
| author_sort | Yoshitaka Saito |
| collection | DOAJ |
| description | Abstract Oral mucositis (OM) is one of the most common complications associated with chemotherapy. Here, we evaluated whether systemic dexamethasone (DEX) dosage in prophylactic antiemetics affected the incidence of OM in anthracycline-containing regimens. Patients receiving anthracycline-containing regimens for breast cancer were divided into high- and low-DEX dose groups and retrospectively evaluated. The incidence of all-grade OM in the first cycle in the high- and low-dose groups was 27.3% and 53.5%, respectively, and was significantly lowered by increasing the DEX dose (P < 0.01); thus, the study met its primary endpoint. The result in all treatment cycles was also significant (P = 0.02). In contrast, the incidence of dysgeusia was similar between the high- and low-dose groups in the first and all cycles (13.6% and 16.3% in the first cycle [P = 0.79] and 27.3% and 34.9% in all cycles [P = 0.42], respectively). Multivariate analysis revealed that low DEX dosage was an independent risk factor for all-grade OM development. In conclusion, our study suggests that DEX attenuates OM in anthracycline-containing regimens for breast cancer treatment in a dose-dependent manner. Further evaluation of OM prophylaxis, including DEX administration, is required for better control. |
| first_indexed | 2024-04-13T20:22:34Z |
| format | Article |
| id | doaj.art-1253602ab3e341cd997c16c0e0737819 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-13T20:22:34Z |
| publishDate | 2022-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-1253602ab3e341cd997c16c0e07378192022-12-22T02:31:28ZengNature PortfolioScientific Reports2045-23222022-07-011211810.1038/s41598-022-16935-4Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatmentYoshitaka Saito0Yoh Takekuma1Takashi Takeshita2Tomohiro Oshino3Mitsuru Sugawara4Department of Pharmacy, Hokkaido University HospitalDepartment of Pharmacy, Hokkaido University HospitalDepartment of Breast Surgery, Hokkaido University HospitalDepartment of Breast Surgery, Hokkaido University HospitalDepartment of Pharmacy, Hokkaido University HospitalAbstract Oral mucositis (OM) is one of the most common complications associated with chemotherapy. Here, we evaluated whether systemic dexamethasone (DEX) dosage in prophylactic antiemetics affected the incidence of OM in anthracycline-containing regimens. Patients receiving anthracycline-containing regimens for breast cancer were divided into high- and low-DEX dose groups and retrospectively evaluated. The incidence of all-grade OM in the first cycle in the high- and low-dose groups was 27.3% and 53.5%, respectively, and was significantly lowered by increasing the DEX dose (P < 0.01); thus, the study met its primary endpoint. The result in all treatment cycles was also significant (P = 0.02). In contrast, the incidence of dysgeusia was similar between the high- and low-dose groups in the first and all cycles (13.6% and 16.3% in the first cycle [P = 0.79] and 27.3% and 34.9% in all cycles [P = 0.42], respectively). Multivariate analysis revealed that low DEX dosage was an independent risk factor for all-grade OM development. In conclusion, our study suggests that DEX attenuates OM in anthracycline-containing regimens for breast cancer treatment in a dose-dependent manner. Further evaluation of OM prophylaxis, including DEX administration, is required for better control.https://doi.org/10.1038/s41598-022-16935-4 |
| spellingShingle | Yoshitaka Saito Yoh Takekuma Takashi Takeshita Tomohiro Oshino Mitsuru Sugawara Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment Scientific Reports |
| title | Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment |
| title_full | Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment |
| title_fullStr | Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment |
| title_full_unstemmed | Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment |
| title_short | Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment |
| title_sort | impact of systemic dexamethasone administration on oral mucositis induced by anthracycline containing regimens in breast cancer treatment |
| url | https://doi.org/10.1038/s41598-022-16935-4 |
| work_keys_str_mv | AT yoshitakasaito impactofsystemicdexamethasoneadministrationonoralmucositisinducedbyanthracyclinecontainingregimensinbreastcancertreatment AT yohtakekuma impactofsystemicdexamethasoneadministrationonoralmucositisinducedbyanthracyclinecontainingregimensinbreastcancertreatment AT takashitakeshita impactofsystemicdexamethasoneadministrationonoralmucositisinducedbyanthracyclinecontainingregimensinbreastcancertreatment AT tomohirooshino impactofsystemicdexamethasoneadministrationonoralmucositisinducedbyanthracyclinecontainingregimensinbreastcancertreatment AT mitsurusugawara impactofsystemicdexamethasoneadministrationonoralmucositisinducedbyanthracyclinecontainingregimensinbreastcancertreatment |